Web Exclusives

KAM principles translate across all business sectors. David Southern and Gary Lunt describe six steps for learning the best from other sectors.

Advice from Tim Harding, customs and tax manager at GEFCO UK, on how to keep medicines moving after the UK departs from the European Union.

Adoption of natural language processing and text analytic technologies across healthcare and life science organisations looks set to accelerate with explosive growth in unstructured data and the growing need to gain relevant insight from it.

Cielo’s Tanya Derrick says building a sustainable talent strategy is key to addressing recruitment challenges in the life sciences industry

Prof Sudhesh Kumar, dean of the Warwick Medical School and board member of NHS Digital, on Japan’s ageing society and the lessons for the UK healthcare market

Organisational psychologist Jane Piper on why we should be doing less to achieve more

The lack of availability of early-stage research, particularly in online repositories, threatens to hinder scientific progress, says Morressier’s Sami Benchekroun

The pharma innovation story isn’t resonating with vital stakeholders: prescribers and payers working in healthcare settings. Data from a global study which surveyed decision-makers in the healthcare sector reveals that only 39% of respondents in the UK saw the pharmaceutical industry as innovative.

The Court of Justice of the European Union (CJEU) has dealt a blow to innovators in two recent significant judgments, addressing questions posed by national courts struggling to judge the eligibility of SPC applications.

Amanda Powel-Smith says pharma has a real opportunity to lead the way in how responsible businesses react to societal challenges

Healthcare communications has always been a bit like Hogwarts. Invisible to most people, massive when you get there, and filled with magic you haven’t yet discovered. There is a creative revolution in healthcare right now.

Former surgeon in training Joost Bruggeman discusses the origins of burnout in the healthcare setting and what the NHS needs to do to resolve it.

Chrissie Jamieson offers her view on what pharma can do to boost brand protection amid the rise of counterfeit medicines

Dr Vlado Perkovictalks to PharmaTimes about his hopes for Novo Nordisk’s FLOW trial, and the need to tackle the growing burden of chronic kidney disease (CKD) in the type II diabetes population.

Richa Munjal considers the current landscape for PCSK9 inhibitors and whether there is a brighter future on the horizon for this class of drugs.